EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
sheet with Nippon Shinyaku Co., Ltd. , a Japanese pharmaceutical company, for the commercialization and distribution in Europe of Capricor's lead asset, deramiocel, for Duchenne muscular dystrophy (DMD) DMD is a genetic disorder characterized by progressive weakness and chronic inflammation of the skeletal, heart, and respiratory muscles. In June, Capricor Therapeutics released three-year results from the ongoing HOPE-2 open-label extension study with CAP-1002 in boys and young men with DMD. According to the results, patients treated with CAP-1002 continued to show benefits after three years of treatment compared to an external comparator dataset of similar DMD patients The company also announced the long-term benefits of deramiocel, showing increased cardiac function based on several different measures The potential transaction covered by the term sheet is similar to the existing Commercialization and Distribution Agreements with Nippon Shinyaku in the United States and Jap
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its price target raised by analysts at Oppenheimer Holdings Inc. from $14.00 to $15.00. They now have an "outperform" rating on the stock.MarketBeat
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $12.00 price target on the stock.MarketBeat
- Capricor Therapeutics Inc (NASDAQ: CAPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.MarketBeat
- Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics Signs Binding Term Sheet with Nippon Shinyaku for European Expansion and Commercialization of Deramiocel for the Treatment of Duchenne Muscular DystrophyGlobeNewswire
CAPR
Earnings
- 8/7/24 - Miss
CAPR
Sec Filings
- 9/17/24 - Form 8-K
- 8/23/24 - Form SC
- 8/23/24 - Form 3
- CAPR's page on the SEC website